Of these individuals, 227 were randomly designated in a 1:1:1:1 ratio to receive placebo or oral bardoxolone methyl at a dosage of 25, 75, or 150 mg once daily for 52 several weeks . The analysis had four intervals: a 21-time screening period; an 8-week amount of dose adjustment that could be extended up to 20 weeks if needed to reach the randomly assigned dosage of bardoxolone methyl; dosage maintenance from the ultimate end of the dose-adjustment period through week 52; and follow-up for four weeks after the last dose. The use of concomitant medications, including antihypertensive agents, was adjusted by the treating physician according to established suggestions.$24.4 million of the customer accounts receivables that became thanks through the quarter ended March 31, 2011 were collected on April 1, 2011. Cash found in investing activities was $1.1 million for the 90 days ended March 31, 2011. 2011 Outlook Predicated on the position of our current contract negotiations and robust pipeline, we are affirming our assistance issued on March 2, 2011. At December 31 We expect our Projected Contracted Annual Income Run Rate, 2011 to exceed $900 million. December 31 For the entire year ended, 2011, we expect net services revenues of $835 million to $850 million and non-GAAP altered EBITDA of $80 million to $86 million. The midpoint of our assistance range for 2011 non-GAAP modified EBITDA represents an 84 percent development over the non-GAAP modified EBITDA in 2010 2010.